Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Featured

Featured Articles

FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured

By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction…

Three-Person In Vitro Fertilization: Combating Mitochon...
April 1, 2013 - Featured , In the News / Politics

By: Bharat Kirthivasan – The UK government might soon become the platform for an explosive debate on the utility and ethics of three-person in vitro fertilization (three-person IVF). According to the Human Fertilization & Embryology Authority, there is no evidence to suggest that any form of IVF is unsafe for the mother or the fetus.…

Say Goodbye to Yearly Flu Shots—The Universal Flu Vac...
April 1, 2013 - Clinical , Featured

By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Every flu season, it is the same story: long lines at doctors’ offices and pharmacy counters as patients scramble to get the year’s vaccine before supplies run out. Year after year, doctors and pharmacists groan while explaining over and over again to patients why they need…

Increased Costs of Treatment due to the DSM-V: Implicat...
April 1, 2013 - Featured , In the News / Politics

By: James W. Schurr and David Gao, PharmD Candidates 2014 – A recent Op-ed in Newsday by Allen Frances, MD (of Duke University School of Medicine and chairman of the task force that produced the DSM-IV, the current guidelines for psychiatric disease diagnosis) criticizes the American Psychiatric Association for being “extravagantly indifferent to all matters…

Documentation of Drug Allergies in Hospitalized Older A...
April 1, 2013 - Clinical , Featured

By: Nandini Puranprashad, PharmD Candidate; Sibyl Cherian, PharmD Candidate; Tracey Cannova, PharmD Candidate; and Olga HilasPharmD, MPH, BCPS, CGP  – Adverse drug reactions are estimated to occur in 10-20% of hospitalized patients and in 7% of the general population.1 One-third of these reactions are of an allergic or pseudo-allergic nature. The consequences of these hypersensitivity…

U.S. v Caronia: Misdemeanor or Constitutional Right?...
March 1, 2013 - Featured , In the News / Politics

By: Tamara Yunusova, Staff Editor – On December 3, 2012, the U.S. Second Circuit Court of Appeals became the first court in the nation to authorize off-label drug promotion under the First Amendment.  The heavily-disputed ruling, which is headed for further appeal, will have far-reaching implications for pharmaceutical companies and drug regulation policy. In a…

New FDA Approval: Fycompa® to Treat Seizures...
March 1, 2013 - Clinical , Featured

By: Bhavini Shah, PharmD Candidate c/o 2013  – Fycompa® (perampanel) has received the U.S. Food and Drug Administration (FDA) approval for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.1  The drug, manufactured by Eisai Inc., is already approved for use in Iceland,…

FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured

By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications.  This…

Extending the Standing Order for Tdap...
February 1, 2013 - Featured , In the News / Politics

By:  Christina Tarantola, PharmD, PGY-1 Resident at Kings Pharmacy – The New York State Department of Health issued a health advisory on November 8, 2012 in response to Hurricane Sandy. The document outlined guidelines on recommended immunizations and disaster relief efforts for volunteers and the general public. Due to an increased risk of exposure to…

A Look at Primary Medication NonAdherence and How it ca...
February 1, 2013 - Featured , In the News / Politics

By:  Erica Dimitropoulos, Assistant Student Editor – Although clinical trials can affirm the efficacy and advantages of all marketed medications, it is obvious that patients cannot benefit from a drug that they choose not to take. Therefore, promoting medication adherence is one of the easiest and most affordable ways to improve treatment outcomes. In order…

Calcium Intake and Risk of Myocardial Infarction...
February 1, 2013 - Clinical , Featured

By:  Lila Ahmed, PharmD Candidate c/o 2013 – In the past, numerous research efforts have attempted to prove the benefits and risks of calcium and multivitamin supplements with little success. Most of the studies performed were inconclusive and did not provide us with significant data; while some studies have found that calcium is beneficial for…

Liraglutide (Victoza®) for Type 2 Diabetes Mellitus...
February 1, 2013 - Clinical , Featured

By:  Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s…

Emerging Pathways For Treating Hepatitis C Virus...
February 1, 2013 - Clinical , Featured

By:  Maria Sorbera, PharmD Candidate c/o 2013, AMSCOP, LIU – Hepatitis C is the leading cause of chronic liver disease and cirrhosis, presenting a global health challenge.  Approximately 170 million people worldwide, 3% of the population, are infected with the Hepatitis C Virus (HCV), roughly 3.2 million of whom reside in the United States.  The…

The Opioid Debate: PROP and PROMPT Battle Away...
January 1, 2013 - Featured , In the News / Politics

By: Tamara Yunusova – On Wednesday, July 25th a petition signed by the reform group Physicians for Responsible Opioid Prescribing (PROP) called on the FDA to implement opioid label changes that would restrict Chronic Non-Cancer (CNCP) opioid treatment for patients with severe pain only.  It wasn’t too long before another petition signed by PROP’s adversary,…

New Healthcare Law Concerning Birth Control Causes Deba...
January 1, 2013 - Featured , In the News / Politics

By: Katie Cimmino, Pharm D. Candidate c/o 2015 –  With the start of the New Year the French government is enacting a new law concerning contraceptives. Now girls between the ages of 15 to 18 will be able to obtain free birth control.  Not only will they have access to it, but the French government…

FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics

By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1  This occurred one month after its approval in  Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is…

White House Petition Seeks to Recognize Pharmacists as ...
January 1, 2013 - Featured , In the News / Politics

By: Mohamed Dungersi, Associate Student Editor – A recent We the People petition on the White House official website has reached the 25,000 signature threshold needed to trigger an official response.  The petition tilted “Recognize pharmacists as health care providers”, was initiated by the current editor in chief of the Rho Chi Post, Steve Soman.1 …

Tackling America’s Drug Shortage Crisis...
December 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions

By: John S Lim, PharmD Candidate c/o 2013 – America’s focus on healthcare, as well as its position as one of the wealthiest nations of the industrialized world, is incongruous with the consequences of drug shortages suffered by its population. Shortages in pharmaceutical supply compromise quality of life while increasing health care costs. The pharmaceutical…

Breakthroughs in Gene Therapy: Pharmacogenetics and Vec...
December 1, 2012 - Clinical , Featured

By: Tamara Yunusova, PharmD Candidate c/o 2017 – Gene therapy? You scoff in disbelief as thoughts of designer babies, liberal eugenics, clones, and ruthless dystopian societies begin to reel in the back of your mind. Perhaps you may even stop to recall a scene or two from Jurassic Park or Star Trek. Undoubtedly, gene therapy…

Adverse Events from Ingestion of OTC Eye Drops and Nasa...
December 1, 2012 - Featured , In the News / Politics

By Tasnima Nabi, PharmD Candidate c/o 2016 – The FDA has issued warnings on accidental ingestion of over-the-counter eye drops and nasal sprays because they can cause serious harm in children at and under the age of five. Ingestion of as little as 0.6 ml of OTC nasal decongestants and redness-relief eye drops has been…

Giving a Second Chance: The Prescription Drug Abuse Epi...
December 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions

By: Maria Sorbera, PharmD Candidate c/o 2013 at AMSCOP (LIU) – Author William S. Burroughs states in his novel, “The question is frequently asked: Why does a man become a drug addict?  The answer is that he usually does not intend to become an addict. You don’t wake up one morning and decide to be…

A Memorable Moment: The White Coat Ceremony...
December 1, 2012 - Events , Featured

By: Tasnima Nabi, PharmD Candidate c/o 2016 – The most memorable moment of a professional’s career is when he or she is handed a symbol of what represents the culture and esteem of the chosen profession. For pharmacy students embarking upon a very intensive yet rewarding path, a white coat welcomes us into the pharmacy…

Mechanisms of NSAID Induced Functional Renal Toxicity...
November 1, 2012 - Clinical , Featured

By: James W.  Schurr & Stephen Argiro, PharmD Candidates c/o 2014 – Patients frequently utilize non-steroidal anti-inflammatory drugs (NSAIDs) for a wide variety of conditions, including but not limited to arthritis, headaches, and generalized pain.  Despite an excellent safety profile, NSAIDs are associated with certain toxicities, including renal complications (particularly among at risk populations).1  Acute…

Ivacaftor (KalydecoTM): Targeting the Core of Cystic Fi...
November 1, 2012 - Clinical , Featured

By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1  The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for…

Low-dose SSRIs for the Overly Sensitive Esophagus...
November 1, 2012 - Clinical , Featured

By Sunhae Chang, PharmD Candidate c/o 2013 – When patients complain of heartburn, the blame usually shifts to gastroesophageal reflux disease (GERD).  Therefore, patients receive the “standard therapies for GERD”: antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), or prokinetics.1,2  Luckily, most patients respond well to these agents.1,2  Unfortunately, the not-as-lucky ones, despite PPI…

Duloxetine’s Effect on Blood Glucose Levels...
October 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Duloxetine is a serotonin (5HT) and norepinephrine (NE) reuptake inhibitor (SNRI) introduced to the US market in 2004, indicated for the treatment of diabetic neuropathic pain.1 A chemical figure of duloxetine is shown [in the PDF].2 It was developed in an effort to mimic tricyclic antidepressant mitigation of neuropathic pain…

NYS Legislature to Ban Selling Tobacco Products in Phar...
October 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions

By: Mahdieh Danesh Yazdi – The views expressed in this article are solely those of the author and do not reflect the views of the Rho Chi Post, Rho Chi Beta Delta Chapter, or St. John’s University College of Pharmacy and Health Sciences.   For the past few months, I have been on rotation at…

The Role of NMDA in Electroconvulsive Therapy and Other...
October 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Electroconvulsive therapy (ECT) is a last-line procedure in the treatment of refractory depression, among other neuropsychological disorders.1 By inducing a seizure, neurotransmitters are released and the disease state may feature a modest mitigation in symptoms.1 Seizure medications such as benzodiazepines and barbiturates are prescribed to increase or heighten the seizure…

Medications Causing Body Temperature Fluctuations...
October 1, 2012 - Clinical , Featured

By: Elsa Thomas, Pharm.D. c/o 2013 – Human body uses various complex mechanisms to maintain its body temperature within a narrow range despite extreme environmental temperature changes as well as physiological changes. Several factors can affect body temperature such as disease states, growth, exercise, hormonal changes, and medications. Hypothermia can occurs as a result of…

Influenza Vaccines: Projected Strains for the 2012—20...
September 1, 2012 - Clinical , Featured

By: Joo Hee Kwon, Pharm.D. Candidate c/o 2013 – There are 3 antigenic types of influenza: A, B, and C. Influenza C causes mild illness and therefore does not cause epidemics.  In contrast, influenza A and B are capable of causing mild to severe flu and in some cases death.  An epidemic can occur depending…

Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured

By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality.  The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.…

Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured

By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries.  ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin).  To guide treatment plans, it is important to identify…

College Of Pharmacy And Health Sciences – Name Ch...
September 1, 2012 - Events , Featured , In the News / Politics

 The College of Pharmacy and Allied Health Professions has officially changed its name to the College of Pharmacy and Health Sciences.  This is the college’s second name change since it was established in 1929. In order to truly encompass the current and future educational goals of the College of Pharmacy and Allied Health Professions, the…

Brand Vs. Generic: What Every Prescriber Should Know...
September 1, 2012 - Clinical , Featured , Professional Advice / Opinions

By: Marina Yermolayeva, PharmD Candidate c/o 2013 – “I’m allergic to the generic; I need the brand name medication,” is a common claim heard by many health care providers.  Managed care organizations get numerous calls from doctors and patients requesting prior authorizations to approve brand name medications whilst there are generic alternatives available on formulary.…

Indications for Dialysis: A Mnemonic And Explanation...
August 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief –  Dialysis is the removal of substances from intravascular circulation by filtration.1  Typically, dialysis is ordered when kidney function declines to 10–15% of normal function.2  The National Kidney Foundation’s Kidney Disease Outcome Quality Initiative (K/DOQI) recommends that planning for dialysis begin when patients reach chronic kidney disease stage 4, which is…

The Unsung Heroes...
August 1, 2012 - Featured , Professional Advice / Opinions

By: Steve Soman, Co-Editor-in-Chief – As Americans, we often admire the courage and sacrifice of the men and women serving our country in the armed forces.  As members of the pharmacy community, we admire the professionalism and achievements of our colleagues making outstanding accomplishments in their respective practice settings.  However, often I think we overlook…

Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics

By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug.   First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing…

Use of Donepezil in Patients with Delirium (but without...
July 1, 2012 - Clinical , Featured

By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Donepezil, brand name Aricept®, is an acetylcholinesterase inhibitor indicated as monotherapy for Alzheimer’s disease, the most common form of dementia.  Cholinergic deficiency in the cortex and basal forebrain contributes to cognitive deficits in these patients.  Donepezil reversibly, noncompetitively inhibits centrally active acetylcholinesterase, the enzyme responsible for…

Artificial Saliva Agents in Xerostomia...
July 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Xerostomia, commonly known as dry mouth, is an anti-muscarinic side effect of numerous medications.  Antidepressants, analgesics, diuretics, and antihistamines have a high propensity to cause xerostomia.1  Xerostomia may also result from Sjogren’s syndrome, Parkinson’s disease, and various chemotherapy agents.2  Traditionally, muscarinic agonists like pilocarpine have been used to reverse xerostomia.…

Understanding Diabetic Ketoacidosis...
July 1, 2012 - Clinical , Featured

By: Mohamed Dungersi, Associate Student Editor –  What is diabetic ketoacidosis (DKA)? Diabetic ketoacidosis (DKA) is an acute complication of uncontrolled diabetes or hyperglycemia. It is usually observed in cases of extreme hyperglycemia (usually in excess of 500 mg/dl, though it can occur over 250 mg/dl).1,2  It is usually characterized by the presence of hyperglycemia,…

The Pathophysiology of Syndeham’s Chorea...
July 1, 2012 - Clinical , Featured

By: Neal Shah, Co Editor-In-Chief – Dyskinesias are abnormal, involuntary movement disorders.  Subsets of dyskinesias include choreas and atheosis.  Chorea is irregular and sporadic contraction of muscles whereas athetosis involves a twisting and writhing of muscles.  These two dyskinesias often occur together and are thus termed choreathetosis.1  Common conditions which feature choreatheosis are Huntington’s, and…

Five Lessons Learned from Being an Assistant Dean...
June 1, 2012 - Featured , Professional Advice / Opinions

By: Laura Gianni Augusto, B.S., Pharm.D., Associate Clinical Professor, Department of Clinical Pharmacy Practice – Laura Gianni Augusto, Pharm.D., R.Ph. is an Associate Clinical Professor in the Department of Clinical Pharmacy Practice at St. John’s University College of Pharmacy and Health Sciences. She served as Assistant Dean for Experiential Pharmacy Education from 2007 to 2011.…

Impact of Gender and Race on the Efficacy on Opiods...
June 1, 2012 - Clinical , Featured

By: Lunbao (Jerry) Huang, Pharm.D.  Candidate c/o 2013 – Pain is a very difficult condition to manage, as clinicians have only subjective findings to work with.  Opioid medications are currently the cornerstones for the management of moderate to severe pain; however, it is often problematic to determine a patient’s real ‘need’ for opioids.  Physicians’ clinical…

The Challenges of Pediatric Clinical Drug Trials and Dr...
June 1, 2012 - Clinical , Featured , Professional Advice / Opinions

By: Shannon Tellier, Associate Student Editor – The disease burden in children outweighs the number of pediatric clinical drug trials currently being conducted.  The lack of data in pediatrics leads to drugs being used off-label and without sufficient knowledge of doses, tolerability, and efficacy.  In 1975, only 22% of products in the electronic Physicians’ Desk…

Transplantation in HIV +/- HBV/HCV Patients...
June 1, 2012 - Clinical , Featured

By: Jayoung Park, Pharm.D. Candidate c/o 2013 – Traditionally, human immunodeficiency virus (HIV)-infected patients have generally been excluded from organ transplantation.1  One of the principal concerns was that immunosuppression would accelerate HIV/acquired immune deficiency syndrome (AIDS), resulting in increased mortality and a “waste” of organs.1 A study entitled, “Opportunistic Infections and Neoplasms Following Liver and…

Naloxone Distribution Programs...
June 1, 2012 - Clinical , Featured , In the News / Politics

By: Mahdieh Danesh Yazdi, Associate Student Editor, with Special Thanks to Dr. Tomasz Jodlowski for his contributions to this article – In the 1990s, major urban and rural areas across the United States grappled with a common problem: drug addiction.  At that time, the drugs of choice were illicit substances (i.e. heroin).  In order to combat…

Rho Chi Post Interview with Dean Mangione...
May 1, 2012 - Featured , Professional Advice / Opinions

By: Mohamed Dungersi & Mahdieh Danesh Yazdi, Associate Student Editors – Each month, the editors at the Rho Chi Post have the opportunity to interview one or more of our faculty members. This month, we had the tremendous opportunity to interview the dean of St. John’s University College of Pharmacy and Allied Health Professions, Dean…

Being Aware of Pharmacy Security and Fraud...
May 1, 2012 - Featured , Professional Advice / Opinions

By: Sanjay Dave, Supervising Pharmacist, Class of 1985 St. John’s University College of Pharmacy and Allied Health Professions – Mr. Sanjay Dave is a St. John’s University College of Pharmacy and Allied Health Professions Graduate, Class of 1985.  Since graduation, he has worked for Pathmark Pharmacies and is currently the supervising pharmacist at Pathmark Pharmacy…

Professor of the Year: Dr. Maidhof...
May 1, 2012 - Featured , Professional Advice / Opinions

By: Mohamed Dungersi, Associate Student Editor – Dr. William Maidhof is an Assistant Professor and Industry Professional in the Clinical Pharmacy Practice department of the St. John’s University College of Pharmacy and Allied Health Professions. He is an alumnus of St. John’s University who graduated in 1999 with a BS in Pharmacy and again in…

Update: FTC Approves Medco and Express Scripts Merger...
May 1, 2012 - Featured , In the News / Politics

By: Mahdieh Danesh Yazdi, with Special Thanks to: Dr. Tomasz Jodlowski – In previous issues, we discussed an upcoming $29.1 billion merger between Express Scripts Inc. and Medco Health Solutions. The merger had been previously delayed by the Federal Trade Commission (FTC). The FTC wanted to verify that this upcoming merger would not violate any antitrust…

Post navigation

← Older posts
Newer posts →


Do You Want to be a Published Author? Submit your Article(s) Today!



Tweets by @RhoChiPost

HOME: Home Page

VOLUMES / ISSUES: 15 . 14 . 13 . 12 . 11 . 10 . 9 . 8 . 7 . 6 . 5 . 4 . 3 . 2 . 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List


Copyright © 2011-2026 Rho Chi Post